Diagnostic value of cytology, thyroglobulin, and combination of them in fine-needle aspiration of metastatic lymph nodes in patients with differentiated thyroid cancer

A systematic review and network meta-analysis

Yixin Xu, MD\textsuperscript{a,}\textsuperscript{∗}, Dapeng Wu, MD\textsuperscript{b}, Wenting Wu, MD\textsuperscript{c}, Jian Jiang, MD\textsuperscript{d}, Cheng Xi, MD\textsuperscript{a}, Niangyuan Ye, MD\textsuperscript{a}, Yibo Wang, MD\textsuperscript{a}, Xuezhong Xu, MD\textsuperscript{a}

Abstract

Background: To investigate the diagnostic performance of cytology (fine-needle aspiration cytology [FNAC]), thyroglobulin (fine-needle aspiration thyroglobulin [FNA-Tg]), and combination of them in the washout of fine-needle aspiration for those patients who have suspicious metastatic lymph nodes of differentiated thyroid cancer.

Methods: Databases, including PubMed, EMBase, Web of Science and Cochrane Library were searched up to June 2019. The quality assessment of diagnostic accuracy scale-2 was used to conduct quality assessments, and publication bias was evaluated using the Deeks funnel plot. STATA version 14.0 was used to perform the meta-analysis.

Results: A total of 2257 patients with 2786 samples of suspicious metastatic lymph nodes of differentiated thyroid cancer were included in the meta-analysis. The results showed that the diagnostic value for detecting lymph node metastasis of differentiated thyroid cancer was as follows: combination of FNAC and FNA-Tg > FNA-Tg > FNAC. All differences of superiority among them are statistically significant. The sensitivity of the combination was 0.968 (95% confidence interval [CI]: 0.942–0.983), the specificity was 0.932 (95% CI: 0.856–0.969), the diagnostic score was 6.036 (95% CI: 4.892–7.181), the diagnostic odds ratio was 418.424 (95% CI: 133.167–1314.729), and the score of summary receiver operating characteristic was 0.99 (95% CI: 0.97–0.99).

Conclusions: The combination of FNAC and FNA-Tg is an excellent procedure in diagnosis of lymph nodes metastasis of patients with differentiated thyroid cancer, which should be highly recommended.

Abbreviations: CI = confidence interval, DOR = diagnostic odds ratio, DTC = differentiated thyroid cancer, FN = false-negative, FNAC = fine-needle aspiration cytology, FNA-Tg = fine-needle aspiration thyroglobulin, FP = false-positive, LN = lymph node, LR = likelihood ratio, NLR = negative likelihood ratio, PLR = positive likelihood ratio, QUADAS = quality assessment of diagnostic accuracy scale, RDOR = relative diagnostic odds ratio, SROC = summary receiver operating characteristic, TgAb = antithyroglobulin, TN = true-negative, TP = true-positive, US = ultrasonography.

Keywords: diagnostic value, differentiated thyroid cancer, fine needle aspiration, lymph nodes metastasis

1. Introduction

Differentiated thyroid cancer (DTC) is the most common endocrine cancer, with ninth place for incidence and mortality rate from 0.4% to 0.5% in both men and women, worldwide.\textsuperscript{[1]} Among them, the papillary cancer accounts for about 70%.\textsuperscript{[2]} The widely accepted risk factor for thyroid cancer is ionizing radiation, especially when exposure is in childhood. Meanwhile, other factors (obesity, smoking, hormonal exposures, and environmental pollution) might also play a specific role in the occurrence and development of cancer.\textsuperscript{[1]}

Patients with DTC generally have a good prognosis, especially those with low-risk disease. The recurrence rate is only 2.8% in patients who received curative surgery in the initial therapy.\textsuperscript{[4]} Nevertheless, the metastatic rate of cervical lymph nodes (LNs) is up to 15% in DTC patients.\textsuperscript{[3]} Therefore, long-term follow-up for patients with DTC, especially those with high-risk, is strongly recommended. In clinic, LNs metastasis was always detected by ultrasonography (US).\textsuperscript{[6]} However, this technique distinguishing benign from metastatic LN is highly depended on the experience of the doctor, which was considered to be
Therefore, US-guided fine-needle aspiration cytology (FNAC) is recommended for histological diagnosis of the LN metastasis for patients with DTC both before and after thyroid surgery. In some instances, the tissue material is inadequate for degeneration and cystic changes. As a result, the sensitivity of FNAC is not satisfactory enough, which varies from 75% to 80%.

Measurement of thyroglobulin in the washout of fine-needle aspiration (fine-needle aspiration thyroglobulin [FNA-Tg]) has been proved to be an additional tool for diagnosis of LN metastasis of DTC, especially for those inadequate material of FNAC. Several studies have demonstrated that FNA-Tg increases the sensitivity of FNA-C in identifying LN metastasis of DTC. However, a combination of FNAC and FNA-Tg can statistically improve the diagnostic accuracy of LN metastasis of thyroid cancer is still lacking in evidence. Whether this combination could be used routinely is unknown.

In this study, we aimed to determine the value of FNAC, FNA-Tg, and combination of FNAC and FNA-Tg for diagnosis of LN metastasis of DTC.

2. Methods

2.1. Literature search strategy

A systematic literature search was performed using PubMed, EMBASE, Web of Science, and Cochrane Library (until June 30, 2019). In each database, the following terms were combined as keywords: (thyroglobulin) and (“fine needle” or “fine-needle” or “fine needle aspiration” or “fine-needle aspiration”) and (thyroid) and (cancer or tumor or carcinoma). All articles sections, including abstracts, studies, and references were reviewed carefully. Articles in the reference list were screened to identify any potentially relevant studies.

This study was conducted in accordance with guidelines of the Declaration of Helsinki. The study and protocol were designed with approval from our institutional review board.

2.2. Inclusion criteria

The inclusion criteria were as follows:

1. patients with DTC;
2. LNs were detected by FNA biopsy before or after thyroidectomy;
3. cytology of FNA material and thyroglobulin level of FNA washout were measured simultaneously;
4. gold standard was the final pathology.

2.3. Exclusion criteria

The exclusion criteria were as follows:

1. articles that reported case reports, reviews, letters, and comments;
2. studies that did not provide precise number of benign or metastatic LN samples according to the classification standard of FNAC, FNA-Tg, or combination of FNAC and FNA-Tg; and
3. non-English publications.

If 2 studies were reported by the same institution, the one with the smaller sample size was excluded.

2.4. Data extraction and quality assessment

All studies were carefully reviewed. Data were extracted from each study by 2 independent researchers, including study ID (first author’s name and publication year), country, the absolute number of patients and LN samples, gauge of fine needle, measurement of FNA washout, thyroid cancer type, cutoffs of FNA-Tg, absolute number of true-positive (TP), false-positive (FP), false-negative (FN) and true-negative (TN) test results and concomitant sensitivity, specificity and diagnostic accuracy. The absolute numbers of TP, FP, FN, and TN test results were retrieved from the articles. If the data were not available, e-mails were sent to the corresponding author to ask for complete data for meta-analysis. Any inconsistencies between reviewers were resolved by a third investigator through discussion.

The quality assessment of diagnostic accuracy scale-2 (QUADAS-2) was used to assess the quality of included diagnostic studies. The QUADAS-2 evaluates studies based on patient selection, index test, reference standard, and timing. The results were categorized into low/high/unclear about each domain.

2.5. Outcomes of interests

First, combined sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were calculated among FNAC, FNA-Tg, and combination of FNAC and FNA-Tg. Meanwhile, diagnostic score and diagnostic odds ratio (DOR) and summary receiver operating characteristic (SROC) curves were examined. Finally, 3 diagnostic tests were compared to identify the optimal method.

2.6. Statistical analyses

We used STATA software version 14.0 (StataCorp, College Station, TX) to perform the meta-analysis. Heterogeneity among studies was tested using Cochran Q and Higgins’ I² statistics. For each article, we constructed data of TP, FP, FN, and TN into a 2 × 2 contingency table. The sensitivity, specificity, PLR, NLR, diagnostic score, and DOR were pooled and combined with their 95% confidence interval (CI) using the bivariate mixed-effects regression model. According to Moses–Littenberg method, SROC curves with pooled sensitivity and specificity were estimated. 0.5 was added to each cell in the table to avoid the calculation problem by having 0 values. The score of SROC was defined as excellent (≥0.97), very good (0.93–0.96), good (0.75–0.92), and reasonable (<0.75), respectively.

PLR above 5 and NLR 0.2 below were considered to provide strong diagnostic value. The post-test probability, calculated with likelihood ratio (LR), based on Bayes theorem, was used to evaluate clinical utility of diagnostic test. Pretest probability = prevalence of target condition. Post-test probability = LR × pretest probability/(1-pretest probability) × [1 − LR]. Diagnostic value between each 2 tests was compared using relative diagnostic odds ratio (RDOR) based on multivariate meta-regression. Publication bias of included studies was estimated using the Deeks funnel plot. A result was defined statistically significant with P < .05.

3. Results

3.1. Search strategy

After searching, 534 articles were identified in PubMed, 1234 in Embase, 449 in Web of Science, and 6 in Cochrane Library.
Besides, 10 articles were identified from the reference list of those researches. After duplicates were removed, 80 articles were screened. Forty-six articles were excluded for reasons of being non-English publications, case reports, or reviews. After reading the full-text articles, those that could not provide a precise data of outcomes of interest, used grouping standards that were different from those under consideration and contained irrelevant subjects were excluded. Finally, 19 articles were included in this meta-analysis (Fig. 1).

3.2. Cohort characteristics and quality of the studies

Nineteen studies were finally included in our analysis.\(^\text{[22–40]}\) Sample sizes varied from 30 to 376. With respect to the study region, 7 studies were performed in Korea, 4 in China, 2 in Turkey, 2 in USA, 1 in Brazil, 1 in Spain, 1 in Italy, and 1 in France. The publication date ranged from 2009 to 2018 (Table 1). All studies provided precise data about FNA-Tg results. All studies except one provided precise data about FNAC results. Nine studies provided precise data about FNAC combined with FNA-Tg results. The golden standard is surgical histological examination result. All of these results were classified as TP, FP, FN, and TN, after compared with the gold standard (Table 2).

Quality assessment was conducted on all articles included in meta-analysis using QUADAS-2. Overall, these studies met most of the quality criteria.

3.3. Diagnostic performance of FNAC and FNA-Tg

The pooled sensitivity and specificity of FNAC were 0.813 (95% CI: 0.742–0.868) and 0.964 (95% CI: 0.852–0.992). The PLR
Table 1

| Author       | Year | Country | Study design | Patients | Female | Samples | Needle (gauge) | FNA-Tg measurement | Cancer type | Cutoffs (ng/mL) | AUC (95% CI) |
|--------------|------|---------|--------------|----------|--------|---------|---------------|-------------------|-------------|----------------|---------------|
| Duval        | 2017 | Brazil  | Prospective  | 38       | 28     | 119     | 21            | EQWA             | Differentiated | 4.41         | 0.984 (0.958, 1.0) |
| Li           | 2016 | China   | Prospective  | 124      | 101    | 163     | 21            | IRMA             | Papillary    | N/A            |               |
| Degertekin   | 2016 | Turkey  | Retrospective| 95       | 40     | 165     | 22            | Unclear          | Papillary    | 1              | 0.963 (0.923, 1.0) |
| Shi          | 2015 | China   | Retrospective| 148      | Unclear| 148     | 23            | IRMA             | Unclear      | 1              | N/A            |
| Jo           | 2015 | Korea   | Retrospective| 273      | 221    | 370     | 23            | IRMA             | Differentiated | 1              | N/A            |
| Zhang        | 2014 | China   | Prospective  | 58       | 42     | 68      | 21–25         | EQWA             | Differentiated | 1              | N/A            |
| Casado       | 2013 | Spain   | Retrospective| 10       | Unclear| 16      | 21–25         | EQWA             | Differentiated | 2              | N/A            |
| Baldini      | 2013 | Italy   | Prospective  | 28       | 21     | 35      | 25            | IRMA             | Differentiated | 1              | N/A            |
| Suh          | 2013 | Korea   | Retrospective| 43       | Unclear| 47      | 23            | IRMA             | Papillary    | 1/10           | N/A            |
| Kim          | 2012 | Korea   | Prospective  | 68       | 52     | 91      | 21–23         | IRMA             | Papillary    | 1              | N/A            |
| Sohn         | 2012 | Korea   | Retrospective| 92       | Unclear| 95      | 23            | IRMA             | Papillary    | N/A            |               |
| Bourmaud     | 2010 | France  | Retrospective| 114      | Unclear| 122     | 27            | IRMA             | Papillary    | 1/10           | 0.67 (0.5783, 0.7956)/0.73 (0.6435, 0.8197) |
| Jeon         | 2009 | Korea   | Retrospective| 47       | Unclear| 76      | 21–23         | IRMA             | Papillary    | 1/10           | 0.955 (0.926, 0.984) |
| Kim          | 2009 | Korea   | Prospective  | 168      | Unclear| 168     | 23            | IRMA             | Papillary    | 1              | N/A            |
| Khadra       | 2018 | USA     | Retrospective| 138      | 106    | 138     | 25            | IRMA             | Papillary    | 1              | N/A            |
| Eun          | 2017 | Korea   | Retrospective| 302      | 226    | 376     | 23            | IRMA             | Papillary    | 1              | N/A            |
| Zhao         | 2017 | China   | Retrospective| 189      | Unclear| 196     | 22            | EQMA             | Papillary    | 1              | 0.999 (0.997, 1.000) |
| Tang         | 2016 | USA     | Prospective  | 97       | 75     | 168     | 22–25         | CIA              | Differentiated | 1              | N/A            |
| Salmaslaghi  | 2010 | Turkey  | Prospective  | 225      | 165    | 225     | 22            | IRMA             | Papillary    | 1              | N/A            |

AUC = area under curve, CI = confidence interval, CIA = chemiluminescent immunoassay, ECLIA = chemiluminescence assay, FNA = fine needle aspiration, ICMA = immunocytolimmunoassay, IRMA = immunoluminometric assay, Tg = thyroglobulin.

and NLR were 22.812 (95% CI: 5.271–98.711) and 0.194 (95% CI: 0.141–0.267). The diagnostic score, DOR and score of SROC were 4.768 (95% CI: 3.330–6.206), 117.695 (95% CI: 27.937–495.832), and 0.91 (95% CI: 0.88–0.93).

Meanwhile, the pooled sensitivity and specificity of FNA-Tg were 0.945 (95% CI: 0.905–0.969) and 0.888 (95% CI: 0.761–0.952). The PLR and NLR were 8.411 (95% CI: 3.790–18.663) and 0.062 (95% CI: 0.037–0.105). The diagnostic score, DOR and score of SROC were 4.908 (95% CI: 4.031–5.785), 135.331 (95% CI: 56.293–325.341), and 0.97 (95% CI: 0.95–0.98).

All of these results were shown in Table 3.

3.4. Diagnostic performance and evaluating clinical application of combination of FNAC and FNA-Tg

The pooled results were showed as follows: sensitivity was 0.968 (95% CI: 0.942–0.983), specificity was 0.932 (95% CI: 0.856–0.969) (Fig. 2A and B). Diagnostic score and DOR were 6.036 (95% CI: 4.892–7.181) and 418.424 (95% CI: 133.167–1314.729). The score of SROC was 0.99 (95% CI: 0.97–0.99) (Fig. 3).

PLR and NLR of FNAC combined with FNA-Tg were 14.172 (95% CI: 6.497–30.912) and 0.034 (95% CI: 0.018–0.064), indicating that this test is good for detecting metastasis of thyroid cancer. Subsequently, we performed the Fagan nomogram to confirm the clinical application of this test. We found that if a pretest probability is 20%, the post-test probability of a positive result is 78%. Meanwhile, an NLR of 0.03 reduces the post-test probability to 1% for a negative test result (Fig. 4).

3.5. Network meta-analysis of FNAC, FNA-Tg, and combination of FNAC and FNA-Tg

The results suggested that the diagnostic value for detecting LN metastasis of thyroid cancer was as follows: FNAC combined with FNA-Tg > FNA-Tg > FNAC. The differences of diagnostic value among them are statistically significant (Table 4).

3.6. Publication bias

There are no publication biases in pooled results of FNAC (P > |t| = 0.253), FNA-Tg (P > |t| = 0.731), and combination of FNAC and FNA-Tg (P > |t| = 0.589), according to Deeks funnel plot (Table 3).

4. Discussion

We demonstrated that combination of FNAC and FNA-Tg was superior to FNA-Tg or FNAC alone in diagnostic value of LNs metastases of DTC. Besides, FNA-Tg is better than FNAC. Moreover, differences of diagnostic value among these 3 methods are statistically significant. Overall, combination of FNAC and FNA-Tg is an excellent diagnostic method (SROC score = 0.99) for LNs metastases of DTC.

Accurate discrimination between benign and metastatic LNs is necessary in the diagnostic management of DTC. US and CT are the primary and noninvasive procedures for both pre- and postoperative assessment of thyroid malignancy. However, the diagnostic accuracy of US was far from satisfactory and CT was not widely accepted because of its high cost.

Cytological examination of FNA samples was reported to be an accurate method, with high sensitivity and specificity, for detection of metastatic LNs in general head and neck malignancies.[41] The diagnosis of cervical LNs metastases of DTC is often complex because in inflammatory lymphadenopathies and non-thyroidal cancer metastases are frequent in this region.[42] Therefore, there are many FP and FN results. The accuracy of FNAC highly depends on the experience of cytopathologist.[43] In the present study, we found that the sensitivity of FNAC is just 0.813 and the SROC score is 0.91, which is far from optimal.
Table 2

Pooled sensitivity, specificity, and accuracy of FNA-Tg, FNAC, and FNAC combined with FNA-Tg.

| Author       | Year | Cutoffs of FNA-Tg | TP  | FP  | FN  | TN  | Sensitivity | Specificity | Accuracy |
|--------------|------|-------------------|-----|-----|-----|-----|-------------|-------------|----------|
| Duval        | 2017 | 4.41              | 87  | 7   | 21  | 48  | 80.5        | 87          | 82.8     |
| Li           | 2016 | 1                 | 87  | 7   | 21  | 48  | 80.5        | 87          | 82.8     |
| Degertekin   | 2016 | 1                 | 34  | 0   | 4   | 14  | 91.9        | 100         | 94.1     |
| Shi          | 2015 | 1                 | 86  | 6   | 8   | 48  | 91.5        | 88.9        | 90.5     |
| Shi          | 2015 | 1                 | 93  | 17  | 1   | 37  | 98.9        | 68.5        | 87.8     |
| Jo           | 2015 | unclear           |     |     |     |     |             |             |          |
| Zhang        | 2014 | 1                 | 44  | 1   | 2   | 21  | 95.7        | 95.5        | 95.6     |
| Casado       | 2013 | 2                 | 9   | 0   | 1   | 6   | 90          | 100         | 94.8     |
| Baldini      | 2013 | 1                 | 24  | 2   | 1   | 5   | 92.3        | 83.3        | 90.6     |
| Suh          | 2013 | 1                 | 34  | 0   | 9   | 100 | 69.2        | 91.5        | 83.8     |
| Suh          | 2013 | 1                 | 34  | 2   | 0   | 11  | 100         | 84.6        | 95.7     |
| Kim          | 2012 | 1                 | 46  | 4   | 3   | 38  | 93.9        | 90.5        | 92.3     |
| Sohn         | 2012 | 1                 | 34  | 25  | 8   | 28  | 80.9        | 52.8        | 65.3     |
| Bournaud     | 2010 | 0.93              | 48  | 1   | 4   | 45  | 92.3        | 97.8        | 94.9     |
| Jeon         | 2009 | 38                | 33  | 2   | 3   | 18  | 94.6        | 90          | 93.4     |
| Kim          | 2009 | 1                 | 114 | 3   | 5   | 36  | 95.8        | 73.5        | 89.3     |
| Khadra       | 2018 | 1                 | 68  | 2   | 3   | 19  | 95.8        | 90.5        | 94.6     |
| Eun          | 2017 | 1                 | 92  | 3   | 14  | 46  | 73.0        | 99.9        | 98.6     |
| Zhao         | 2017 | 1                 | 105 | 0   | 5   | 85  | 95.5        | 100.0       | 97.4     |
| Tang         | 2016 | 1                 | 20  | 5   | 1   | 117 | 95.2        | 95.9        | 95.8     |
| Salmi2121    | 2010 | 1                 | 200 | 55  | 0   | 0   | 100.0       | 78.4        | 83.1     |

FNAC = fine needle aspiration cytology, FNA-Tg = fine needle aspiration thyroglobulin, FN = false-negative, FP = false-positive, TN = true-negative, TP = true-positive.
FNA-Tg measurement in the washout was originally proposed by Pacini et al in 1992.\(^{[44]}\) This study suggested that high dose of FNA-Tg was always associated with LNs metastasis of thyroid cancer after initial therapy, including thyroidectomy and radioactive iodine ablation, whereas undetectable FNA-Tg frequently indicated benign disease, such as inflammatory or lymphadenopathy. In last decade, several studies proved that the sensitivity and specificity of FNA-Tg for diagnosis of LN metastasis of DTC are superior to FNAC.\(^{[11,42,43]}\) In the present study, we found that the diagnostic value of FNA-Tg is superior to FNAC with statistical difference.

### Table 3

Summary of the results of combined sensitivity, specificity, positive, and negative likelihood ratio for FNAC, FNA-Tg, and FNAC + FNA-Tg.

| Test                  | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | Diagnostic score (95% CI) | DOR (95% CI) | SROC (95% CI) | P > |j| |
|-----------------------|----------------------|----------------------|--------------|--------------|---------------------------|--------------|---------------|------|----|
| FNAC                  | 0.813 (0.742, 0.868) | 0.964 (0.852, 0.992) | 22.812 (5.271, 98.711) | 0.194 (0.141, 0.267) | 4.768 (3.330,6.206) | 117.695 (27.837, 495.832) | 0.91 (0.88, 0.93) | .253 |
| FNA-Tg                | 0.945 (0.905, 0.969) | 0.888 (0.761, 0.952) | 8.411 (3.790, 18.063) | 0.062 (0.032, 0.105) | 4.908 (4.031, 5.785) | 135.331 (56.293, 325.341) | 0.97 (0.95, 0.98) | .731 |
| FNAC+FNA-Tg           | 0.968 (0.942, 0.983) | 0.932 (0.856, 0.968) | 14.172 (6.497, 30.912) | 0.034 (0.018, 0.064) | 6.036 (4.892, 7.181) | 418.424 (133.167, 1314.729) | 0.99 (0.97, 0.99) | .589 |

AUROC = area under the receiving-operation curve, DOR = diagnostic odds ratio, FNAC = fine needle aspiration, FNA = fine needle aspiration cytology, NLR = negative likelihood ratio, PLR = positive likelihood ratio, Tg = thyroglobulin.

---

**Figure 2.** The diagnostic accuracy index of the combination of FNA and FNA-Tg. (A) Sensitivity, (B) Specificity. FNA = fine-needle aspiration, FNA-Tg = fine-needle aspiration thyroglobulin.

**Figure 3.** SROC curve of the combination of FNA and FNA-Tg. FNA = fine-needle aspiration, FNA-Tg = fine-needle aspiration thyroglobulin, SROC = summary receiver operating characteristic.
However, there are still some problems with this method. First, normal thyroid tissue synthesizes and secretes Tg, and its concentration in blood is closely associated with the size of thyroid, hormones, and antithyroglobulin (TgAb). Tg and TgAb are antagonistic to each other. Baskin et al first suggested that TgAb in the peripheral blood would not affect the measurement of FNA-Tg in the washout, possibly because intracellular Tg is not exposed to circulating TgAb.[45] After 2 years, Boi et al also identified that the diagnostic performance of FNA-Tg seemed to be not affected by TgAb.[46] It is possibly because concentration of FNA-Tg in LN metastasis is much higher than TgAb in the washout fluid. The effect of TgAb on FNA-Tg is almost negligible. In addition, the dilution of washout fluid (1:50 or higher) results in the scarcity of TgAb. Nevertheless, a lower sensitivity and NPV of FNA-Tg in diagnosis of LN metastasis of DTC was found by Jeon et al in 2013,[47] which means the serum TgAb levels could lower the diagnostic performance of FNA-Tg. The same result was identified by Jo et al in 2015.[28] Therefore, the interference of TgAb to FNA-Tg is still controversial. There are various ways to identify the FNA-Tg threshold values, including mean + 2 standard deviation of FNA-Tg concentration in patients without LNs metastases, highest Tg concentration in patients with reactive LNs, FNA-Tg more than serum Tg level, fixed Tg values, and so on. Pak et al published a meta-analysis suggested that the best pre and postoperative cutoff value of FNA-Tg for diagnosis of LN metastasis of DTC were 0.9 ng/mL and 32.04 ng/mL, respectively.[43] Another study suggested that the optimal cutoff value of FNA-Tg was 2.24 ng/mL and 1.09 ng/mL for patients before and after thyroidectomy, respectively.[48] However, in the process of collecting information for the present study, we found that most studies defined the cutoff value of FNA-Tg as 1 ng/mL or 10 ng/mL. The main purpose of the present study is not to identify the optimal cutoff value of FNA-Tg, so the subgroup analysis has not been performed. The diagnostic value of FNA-Tg in LN metastasis of DTC should not be ignored, despite the controversy of optimal cutoff value. In addition, the subject of best cutoff value of FNA-Tg should be studied in more clinical trials.

Due to limited financial condition and the deficiency of equipment, not all of the hospitals are able to test both the FNAC and FNA-Tg at the same time. Most of them only use the FNAC as the primary diagnostic method for suspicious DTC patients. However, according to the guidelines of European, Korean, and American Thyroid Association, the combination of FNAC and FNA-Tg is recommended for the patients with suspicious DTC.[49–51] Its diagnostic accuracy is statistically superior. Our study found that a combination of FNAC and FNA-Tg had statistically better diagnostic performance than FNAC or FNA-Tg alone. The score of SROC is 0.99, which means this is an excellent diagnostic method of LN metastasis of DTC. Meanwhile, the Fagan nomogram showed that the clinical application of combination of FNAC and FNA-Tg was obvious. The results showed that if the test is negative, the probability of LN metastasis of DTC would decrease only to 1%, but if the test is positive, the probability of LN metastasis of DTC would increase to 78%. Li et al also identified the same conclusion in their study published in 2016.[33] For those obvious metastatic LNs, the level of FNA-Tg is frequently extremely high. However, for those FNA tissues, the FNA-Tg level of which is near the cutoff value, the FNAC could be used as additional diagnostic method to identify the histological result. Meanwhile, for those inadequate tissues of FNAC, the FNA-Tg is also an ideal additional diagnostic procedure.

There are some limitations of our study. Some studies did not have precise data, as we sent an email to the author asking for them.
but the email had no response. Some results of our study had apparent heterogeneity. The sources of heterogeneity did not be found after regression and heterogeneity analysis.

In conclusion, combination of FNA and FNA-Tg is an excellent diagnostic procedure for LN metastasis of DTC. Compared to FNAC and FNA-Tg alone, the combination could statistically improve the diagnostic performance. This procedure should be recommended for patients with suspicious LN metastasis of DTC before or after initial therapy.

Acknowledgments

The authors thank Dr. Peng Jiang and Dr. Haifeng Tang for their critical reading and informative advice during the process of study.

Author contributions

Conceptualization: Yixin Xu.

Data curation: Yixin Xu, Dapeng Wu, Wenting Wu, Jian Jiang.

Formal analysis: Dapeng Wu, Cheng Xi.

Methodology: Cheng Xi, Nianyuan Ye.

Software: Nianyuan Ye.

Writing – original draft: Yibo Wang, Xuezhong Xu.

Writing – review and editing: Yixin Xu.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
[2] Lloyd RV, Buehler D, Khanzadkar E. Papillary thyroid carcinoma variants. Head Neck Pathol 2011;5:51-6.
[3] Thun MJ, Lint M, Gerhan JR, et al. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. Fourth edition New York, NY: Oxford University Press 2018.
[4] Scheffel RS, Zanella AB, Antunes D, et al. Low recurrence rates in a cohort of differentiated thyroid carcinoma patients: a referral center experience. Thyroid 2015;25:883-9.
[5] Wunderbaldinger P, Harisinghani MG, Hahn PF, et al. Cystic lymph node metastases in papillary thyroid carcinoma. AJR Am J Roentgenol 2002;178:693-7.
[6] Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
[7] Schiumberger M. Papillary and follicular thyroid carcinoma. Ann Endocrinol (Paris) 2007;68:120-8.
[8] Takashima S, Sone S, Nomura N, et al. Nonpalpable lymph nodes of the neck: assessment with US and US-guided fine-needle aspiration biopsy. J Clin Ultrasound 2015;23:829-32.
[9] Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab 2004;99:1970-82.
[10] Chung J, Kim EK, Lim H, et al. Optimal indication of thyroglobulin measurement in fine-needle aspiration for detecting lateral metastatic lymph nodes in patients with papillary thyroid carcinoma. Head Neck 2014;36:795-801.
[11] Min JK, Kim EK, Kim BM, et al. Thyroglobulin measurement in fine-needle aspiration washout: the criteria for neck node dissection for patients with thyroid cancer. Clin Endocrinol (Oxf) 2009;70:145-51.
[12] Sohn Y-M, Kim MJ, Kim EK, et al. Diagnostic performance of thyroglobulin value in indeterminate range in fine needle aspiration washout fluid from lymph nodes of thyroid cancer. Yonsei Med J 2012;53:126-31.
[13] Whiting PR, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
[14] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
[15] Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1995;12:1293-316.
[16] Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg 2005;79:16-20.
[17] Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-62.
[18] Jaeschke R, Guyatt GH, Sackett DL. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994;271:703-7.
[19] Jaeschke R, Guyatt G, Sackett DL, et al. Users’ guides to the medical literature: III. How to use an article about a diagnostic test A. Are the results of the study valid? JAMA 1994;271:389-91.
[20] White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J 2011;11:255-70.
[21] Dan J, Riley R, White IR. Multivariate meta-analysis: potential and promise. Stat Med 2011;30:2481-98.
[22] Baldini E, Sorrenti S, Di Gioia C, et al. Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology? BMC Clin Pathol 2013;13:7.
[23] Bournaud C, Charrie A, Noziere E, et al. Thyroglobulin measurement in fine-needle aspirates of lymph nodes in patients with differentiated thyroid cancer: a simple definition of the threshold value, with emphasis on potential pitfalls of the method. Clin Chem Lab Med 2010;48:1711-7.
[24] Duval M, Zanella AB, Cristo AP, et al. Impact of serum TSH and anti-thyroglobulin antibody levels on lymph node fine-needle aspiration thyroglobulin measurements in differentiated thyroid cancer patients. Eur Thyroid J 2017;6:292-7.
[25] Eun NL, Son EJ, Kim JA, et al. Comparison of the diagnostic performances of ultrasonography, CT and fine needle aspiration cytology for the prediction of lymph node metastasis in patients with lymph node dissection of papillary thyroid carcinoma: a retrospective cohort study. Int J Surg 2018;51:145-50.
[26] Familiar Casado C, Antron Bravo T, Moraga Guerrero I, et al. The value of thyroglobulin in washout of fine needle aspirate from 16 cervical lesions in patients with thyroid cancer. Endocrino Nutr 2013;60:495-503.
[27] Jeon SJ, Kim E, Park JS, et al. Diagnostic benefit of thyroglobulin measurement in fine-needle aspiration for diagnosing metastatic cervical lymph nodes from papillary thyroid cancer: correlations with US features. Korean J Radiol 2009;10:106-11.
[28] Jo K, Kim MH, Lim Y, et al. Lowered cutoff of lymph node fine-needle aspiration thyroglobulin in thyroid cancer patients with serum anti-thyroglobulin antibodies. Eur J Endocrinol 2015;173:489-97.
[29] Khadra H, Mohamed H, Al-Qurayshi Z, et al. Superior detection of metastatic cystic lymphadenopathy in patients with papillary thyroid cancer by utilization of thyroglobulin washout. Head Neck 2019;41:225-9.
[30] Kim DW, Jeon SJ, Kim CG. Usefulness of thyroglobulin measurement in needle washouts of fine-needle aspiration biopsy for the diagnosis of cervical lymph node metastases from papillary thyroid cancer before thyroidectomy. Endocrine 2012;42:399-403.
[31] Kim MJ, Kim EK, Kim BM, et al. Thyroglobulin measurement in fine-needle aspirate washouts: the criteria for neck node dissection for patients with thyroid cancer. Clin Endocrinol (Oxf) 2009;70:145-51.
[32] Konca Degertekin C, Yalcin MM, Cerrit T, et al. Lymph node fine-needle aspiration washout thyroglobulin in papillary thyroid cancer: diagnostic value and the effect of thyroglobulin antibodies. Endocr Res 2016;41:281-9.
[33] Li J, Zhang K, Liu X, et al. Cervical lymph node thyroglobulin measurement in washout of fine-needle aspirates for diagnosis of papillary thyroid cancer metastases. Br J Biomed Sci 2016;73:79-83.
[34] Salmasloaug A, Ezbel Y, Citak G, et al. Diagnostic value of thyroglobulin measurement in fine-needle aspiration biopsy for detecting metastatic lymph nodes in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 2011;396:77-81.
[35] Shi JH, Xu YY, Pan QZ, et al. The value of combined application of ultrasound-guided fine needle aspiration cytology and thyroglobulin measurement for the diagnosis of cervical lymph node metastases from thyroid cancer. Pak J Med Sci 2015;31:1152-3.
[36] Sohn YM, Kim MJ, Kim EK, et al. Diagnostic performance of thyroglobulin value in indeterminate range in fine needle aspiration washout fluid from lymph nodes of thyroid cancer. Yonsei Med J 2012;53:126–31.
[37] Suh YJ, Son EJ, Moon HJ, et al. Utility of thyroglobulin measurements in fine-needle aspirates of space occupying lesions in the thyroid bed after thyroid cancer operations. Thyroid 2013;23:280–8.
[38] Tang S, Back A, Jones C, et al. The utility of thyroglobulin washout studies in predicting cervical lymph node metastases: one academic medical center’s experience. Diagn Cytopathol 2016;44:964–8.
[39] Zhang HS, Wang RJ, Fu QF, et al. Diagnostic value of thyroglobulin measurement with fine-needle aspiration biopsy for lymph node metastases in patients with a history of differentiated thyroid cancer. Asian Pac J Cancer Prev 2014;15:10905–9.
[40] Zhao H, Wang Y, Wang MJ, et al. Influence of presence/absence of thyroid gland on the cutoff value for thyroglobulin in lymph-node aspiration to detect metastatic papillary thyroid carcinoma. BMC Cancer 2017;17:296.
[41] Pomorski L, Kaczka K, Piaskowski S, et al. Detection of lymph node metastases of papillary thyroid cancer—comparison of the results of histopathology, immunohistochemistry and reverse transcription-polymerase chain reaction—a preliminary report. Langenbecks Arch Surg 2005;390:209–15.
[42] Zanella AB, Meyer ELS, Balzan L, et al. Thyroglobulin measurements in washout of fine needle aspirates in cervical lymph nodes for detection of papillary thyroid cancer metastases. Arq Bras Endocrinol Metabol 2010;54:550–4.
[43] Pak K, Suh S, Hong H, et al. Diagnostic values of thyroglobulin measurement in fine-needle aspiration of lymph nodes in patients with thyroid cancer. Endocrine 2015;49:70–7.
[44] Pacini F, Fugazzola L, Lippi F, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 1992;74:1401–4.
[45] Baskin HJ. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid 2004;14:959–63.
[46] Boi F, Baghino G, Atzeni F, et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 2006;91:1364–9.
[47] Jeon MJ, Park JW, Han JM, et al. Serum antithyroglobulin antibodies interfere with thyroglobulin detection in fine-needle aspirates of metastatic neck nodes in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013;98:153–60.
[48] Moon JH, Kim YI, Lim JA, et al. Thyroglobulin in washout fluid from lymph node fine-needle aspiration biopsy in papillary thyroid cancer: large-scale validation of the cutoff value to determine malignancy and evaluation of discrepant results. J Clin Endocrinol Metab 2013;98:1061–8.
[49] Leenhardt L, Erdogan MF, Hegedus L, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2013;2:147–59.
[50] Yi KH. The revised 2016 Korean thyroid association guidelines for thyroid nodules and cancers: differences from the 2015 American Thyroid Association Guidelines. Endocrinol Metab (Seoul) 2016;31:373–8.
[51] Cooper DS, Doherty GM, Haugen BR, et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerRevised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214.